Lunai Bioworks Secures First Licensing LOI Following Landmark Breakthrough Showing Complete Tumor Regression in Humanized Cancer Models

Following peer-reviewed publication and independent expert review of findings, the LOI advances Lunai's tumor-regressing immune-cell platform toward scalable therapies for aggressive cancers SACRAMENTO, Calif., Nov. 25, 2025 /PRNewswire/ -- Lunai Bioworks (NASDAQ: LNAI), an AI-powered...

Read More